Alpha Tau Medical Ltd.

Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange

Alpha Tau Medical's ordinary shares will be added to the Tel Aviv Stock Exchange's TA-90 and TA-125 benchmark indices effective Nov. 5, 2026, within months of its August 2026 dual listing on Nasdaq and TASE. Index funds tracking these benchmarks are expected to add Alpha Tau shares to their holdings, and the company will be one of only three biomed names in the TA-125. CEO Uzi Sofer said the inclusion should raise visibility with Israeli institutional investors, broaden the local shareholder base, and improve liquidity for shareholders globally.

•3d ago

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Alpha Tau Medical signed an MOU with Samsung Medical Center in Seoul to explore a potential Alpha DaRT clinical trial in pancreatic cancer patients — the therapy's first planned trial in South Korea. Any trial remains subject to regulatory and ethics committee approvals, and the MOU is exploratory with no financial terms disclosed. CEO Uzi Sofer said Korea could extend the company's pancreatic cancer program to six countries across four regions, though the announcement is an early-stage collaboration step.

•10d ago

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Alpha Tau Medical won FDA approval of an IDE supplement expanding its U.S. REGAIN trial of Alpha DaRT in recurrent glioblastoma from 10 to 20 patients. The updated protocol adds progression-free survival as a secondary endpoint, quality-of-life assessments, eligibility for IDH-mutant grade 4 tumors, and an interim analysis six months after the fifth patient's July 2026 treatment. An abstract from principal investigator Dr. Joshua Palmer will be presented at the SNO 2026 Annual Meeting on November 13 with new trial data; the company says the expanded dataset may support market submission requirements in this indication.

•13d ago

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau reported a net loss of $68.8 million for the six months ended June 30, 2026, widening from $18.8 million in the prior year, primarily due to a $41.4 million non-cash remeasurement of warrant liability. The company strengthened its balance sheet with $104.8 million in cash and deposits and announced a strategic collaboration with Tolmar for prostate cancer, backed by a $20 million equity investment at a 25% premium and $15 million for U.S. manufacturing. Operationally, the REGAIN glioblastoma trial demonstrated 100% local disease control with a 67% complete response rate, prompting FDA clearance to complete enrollment, while the pivotal ReSTART cSCC trial fully enrolled 88 patients.

•2mo ago

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Alpha Tau Medical intends to dual-list its ordinary shares on the Tel Aviv Stock Exchange, allowing trading in both local currency and business hours alongside its existing Nasdaq listing. The registration encompasses approximately 92.5 million outstanding ordinary shares and potential future issuances related to warrants, options, and employee plans. CEO Uzi Sofer cited strong demand from the Israeli investor base, describing the move as a return to the company's home market ecosystem.

•2mo ago

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical treated the first patient in the ADMIRE study, which evaluates Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The trial targets a vulnerable population of approximately 17 million U.S. adults who face a 65- to 100-fold higher risk of cSCC and cannot use standard immunotherapies due to organ rejection risks. This milestone follows the recent completion of patient enrollment in the company's pivotal ReSTART trial for recurrent cSCC.

•3mo ago

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical successfully treated the first recurrent glioblastoma patient outside the U.S. using its Alpha DaRT technology at Hadassah University Medical Center in Israel. The procedure utilized the company's proprietary brain applicator and stereotactic neuro-navigation to deliver radiation sources via a minimally invasive burr hole, with no unexpected complications reported. This milestone supports the ongoing broad-access ALL protocol and adds momentum to the U.S. REGAIN trial, targeting patients with limited therapeutic options.

•4mo ago

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

The FDA cleared Alpha Tau to resume enrollment in its REGAIN trial for recurrent glioblastoma, allowing recruitment of the final seven patients. This decision follows a pre-specified interim safety report from the first three patients, which showed 100% local disease control and a 67% complete response rate with only one manageable grade 3 adverse event. The company also added two new U.S. academic cancer centers to the trial, expanding geographic access and clinical expertise for this high-unmet-need indication.

•4mo ago

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau reported Q1 2026 results with a net loss of $22.9 million, widening from $8.7 million in the prior year, driven largely by a $9.6 million charge from warrant liability remeasurement. The company highlighted strong clinical progress, including 100% local disease control in early glioblastoma and pancreatic cancer trials, and the completion of enrollment in its pivotal ReSTART trial for cutaneous squamous cell carcinoma. With $80.2 million in cash and equivalents, Alpha Tau maintains sufficient runway to fund ongoing clinical studies and commercial preparation in Japan, where it holds marketing approval for head and neck cancer.

•5mo ago

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau Medical presented pooled results from two first-in-human trials of its Alpha DaRT therapy in pancreatic cancer, showing a 100% local disease control rate across 19 evaluable patients. The safety profile was favorable, with device-associated adverse events occurring in only 27% of treated subjects, nearly all of which resolved within two weeks. Management highlighted the significance of these results in a heavily pre-treated population, noting the treatment's design for seamless integration into standard endoscopic workflows.

•5mo ago